Interaction between tumor stage and age on survival outcomes of patients with anaplastic thyroid cancer

Table 2 Crude analysis of factors associated with all-cause mortality and cancer related mortality among United States patients diagnosed with anaplastic thyroid cancer between 2010 and 2017

Characteristics	Overall mortality	Cancer related mortality
	Crude proportional, HR (95%CI)	Crude proportional, HR (95%CI)
Gender
Female	1 (Reference)	1 (Reference)
Male	0.97 (0.80-1.16)	0.96 (0.89-1.16)
Age at diagnosis, year old
00-59	1 (Reference)	1 (Reference)
60-79	1.38 (1.10-1.74)b	1.29 (1.02-1.64)a
80 +	1.64 (1.24-2.16)b	1.16 (1.19-2.08)b
Marital status
Married	1 (Reference)	1 (Reference)
Single	1.00 (0.77-1.30)	0.94 (0.71-1.23)
Divorced/separated	0.77 (0.54-1.11)	0.76 (0.52-1.11)
Widowed	1.23 (0.97-1.56)	1.22 (0.96-1.55)
Tumor stage
Localized	1 (Reference)	1 (Reference)
Regional by direct extension only	2.12 (1.22-3.66)b	2.07 (1.16-3.66)a
Regional lymph nodes involved only	1.58 (0.81-3.09)	1.59 (0.79-3.20)
Regional by both direct extension and lymph node involvement	1.75 (1.02-3.00)a	1.82 (1.04-3.19)a
Distant	3.24 (2.05-5.12)b	3.25 (2.01-5.24)b
Race
Non-Hispanic white	1 (Reference)	1 (Reference)
Non-Hispanic black	1.12 (0.79-1.59)	1.11 (0.78-1.59)
Hispanic	1.23 (0.96-1.58)	1.22 (0.94-1.57)
Other	1.30 (0.98-1.71)	1.27 (0.95-1.69)
Living area
Counties in metropolitan areas of 1 million persons	1 (Reference)	1 (Reference)
Counties in metropolitan areas of 250000 to 1 million persons	1.11 (0.89-1.38)	1.11 (0.89-1.39)
Counties in metropolitan areas of 250000 persons	0.74 (0.46-1.18)	0.77 (0.47-1.24)
Nonmetropolitan counties adjacent to a metropolitan area	0.80 (0.55-1.14)	0.80 (0.55-1.16)
Nonmetropolitan counties not adjacent to a metropolitan area	1.41 (0.93-2.15)	1.49 (0.98-2.27)
Income per year
$ < $45000	1 (Reference)	1 (Reference)
$45000-54999	0.92 (0.55-1.54)	0.86 (0.51-1.45)
$55000-64999	1.35 (0.85-2.17)	1.28 (0.80-2.06)
$65000-74999	1.01 (0.64-1.60)	0.96 (0.60-1.52)
$75000 +	0.90 (0.57-1.43)	0.85 (0.54-1.34)
Radiation
No	1 (Reference)	1 (Reference)
Yes	0.61 (0.50-0.74)b	0.59 (0.49-0.72)b
Chemotherapy
No	1 (Reference)	1 (Reference)
Yes	0.61(0.50-0.73)b	0.60(0.49-0.72)b
Surgery
No	1 (Reference)	1 (Reference)
Yes	0.50 (0.41-0.59)b	0.47 (0.39-0.58)b

^aP < 0.05.

^bP < 0.01.

HR: Hazard ratio.